Olsen GM, Hansen LM, Stefanko NS, et al. - Among 76 patients (median age at propranolol initiation, 56 days [range, 0-396 days]) with PHACE (posterior fossa malformations, hemangioma, arterial anomalies, cardiac defects, eye anomalies) syndrome receiving oral propranolol for infantile hemangioma, researchers conducted this multicenter retrospective cohort study to evaluate the incidence of adverse events. During treatment with oral propranolol, there were no reports of serious adverse events (ie, stroke, transient ischemic attack, or cardiovascular events). Sleep disturbances and minor gastrointestinal tract and respiratory tract symptoms were the most commonly reported nonserious adverse events. This data provide evidence in this patient population for the safety of oral propranolol.